Evaluation of the Antihyperglycemic Effects of Sapparin Tablets in Streptozotocin+High Fat Diet-Induced Diabetic Rats
- VernacularTitle:Туршилтын амьтанд үүсгэсэн чихрийн шижин хэв шинж 2 эмгэгт Саппарин шахмал эмийн үзүүлсэн зарим үр дүн
- Author:
DA WA
1
;
2
;
Dejidmaa B
3
;
Erdenechimeg Ch
3
;
Anu A
3
;
Chimedragchaa Ch
3
;
Tsend-Ayush D
4
Author Information
1. Department of Internal Medicine, International School of Mongolian Medicine, MNUMS
2. Department of Gal zasal, Inner Mongolia International Mongolian Hospital, Hohhot, China
3. Institute of Traditional Medicine and Technology
4. International School of Mongolian Medicine, MNUMS
- Publication Type:Journal Article
- Keywords:
Streptozotocin;
Traditional medicine;
Diabetes mellitus
- From:
Mongolian Journal of Health Sciences
2026;96(6):145-150
- CountryMongolia
- Language:Mongolian
-
Abstract:
Background:Diabetes mellitus accounts for 42.9% of endocrine and nutritional metabolic diseases in Mongolia, with a prevalence of 111.4 cases per 10,000 population. This represents a 28.5% increase compared with the previous year (82.9 cases per 10,000 population in 2019), indicating a continuing upward trend in the prevalence of diabetes mellitus. In Mongolian traditional medicine, Sapparin tablets are used to treat blood disorders and liver diseases. The formulation contains four major herbal ingredients: C. jubata, C. sappan, Z. officinale, and H. rhamnoides.
Aim:To study the effects of Sapparin in a high-fat diet and low-dose streptozotocin-induced diabetic model in experimental rats.
Materials and Methods:We used 40 Wistar rats to establish a type 2 diabetes mellitus (T2DM) model according to the method described by Bailu Duan et al. (2017). The rats were fed a high-fat diet for 28 days, followed by an intraperitoneal injection of streptozotocin (STZ) at 35 mg/kg to induce T2DM. After STZ administration, Sapparin was orally administered to diabetic rats at 89 and 178 mg/kg for 21 days. At the end of the experimental period, insulin, GLUT4, superoxide dismutase (SOD), and glucagon-like peptide-1 (GLP-1) levels were determined using enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions on days 14 and 21.
Result:After 14 and 21 days of treatment, fasting blood glucose levels decreased by 33% and 22.5% in the Sapparin 89 mg/kg and 178 mg/kg groups, respectively, compared with the diabetic control group (p=0.05). In the glucose tolerance test, the 89 mg/kg Sapparin-treated group showed a 31% increase in glucose levels at the initial measurement compared with the diabetic control group, followed by decreases of 10% at 30 min and 30% at 120 min (p=0.04). Serum insulin levels in the 89 mg/kg Sapparin group decreased by 20% on day 14 and 19.8% on day 21 compared with the diabetic control group, while the 178 mg/kg group showed decreases of 15% and 20%, respectively, approaching the levels observed in the healthy control group (p=0.05). Furthermore, HOMA-IR decreased by 42–46% over time in both the 89 and 178 mg/ kg Sapparin-treated groups, with statistically significant differences observed (p=0.05).
Conclusion:In a rat model of type 2 diabetes mellitus, Sapparin reduced blood glucose levels, serum insulin levels, and insulin resistance (HOMA-IR), and may have a positive effect on lipid metabolism.
- Full text:202609270033018093425_Туршилтын амьтанд үүсгэсэн чихрийн шижин хэв шинж 2 эмгэгт Саппарин шахмал.pdf
